Nucleic acid-based medications such as mRNA vaccines offer tremendous potential for medicine and are opening up new therapeutic approaches. These active ingredients must be enclosed inside nanoparticles to ensure that they get to where they are needed inside the body’s cells.
The Fraunhofer Institute for Production Systems and Design Technology IPK and FDX Fluid Dynamix GmbH have worked together to develop a technology platform for the production of nanoparticles that can achieve particle quality and stability at levels previously out of reach: FDmiX, short for Fraunhofer Dynamic Mixing Technologies. Swiss chemical and pharmaceutical company Lonza has now licensed the technology for its own good manufacturing practice (GMP) production activities.
RNA and DNA, both nucleic acids, are not only found in cells; they can also be components of medications. One common example widely known from the coronavirus pandemic is mRNA vaccines.
Medical professionals the world over are very hopeful about nucleic acid-based active ingredients, which offer potential as therapies for diseases that were previously difficult to treat, including some forms of cancer. However, safely and effectively transporting these sensitive nucleic acids to the cells, where the messages they carry can be translated into proteins, has proven to be a significant challenge thus far.
A protective envelope is needed to get the sensitive active ingredient into the cells. These nanoparticles are produced using fluid mixing processes. Very thorough, rapid mixing is necessary to produce particles of the requisite quality. Impinging jet mixers (also known as T-mixers or Y-mixers) are available for industrial-scale applications. They enable high throughput, but at the expense of mixing quality.
Better, faster mixing
In the Fraunhofer Dynamic Mixing Technologies (FDmiX) platform, Fraunhofer IPK and FDX Fluid Dynamix GmbH have managed to bridge the gap between mixing quality and throughput. The FDmiX platform allows for consistently high mixing quality at any scale, from the lab right up to mass production. It has already successfully passed tests aimed at production of lipid and polymer nanoparticles and of nanoemulsions.
As extensive testing has shown, the mixing quality of the FDmiX technology platform is superior to the systems that have been available to date, enabling production of particles at previously unattainable levels of quality.
The system is also impressive in terms of its scaling capability, as encapsulation can take place with volume streams ranging from 5 ml/min to 1.5 l/min without affecting the particle properties.
Lonza, a global development and production partner to the pharmaceutical, biotech, and neutraceuticals markets, has licensed the patented FDmiX technology and is already using it.
“Human cells defend themselves against foreign genetic material. That’s why the mRNA active ingredients have to be enclosed inside nanoparticles. So the particles act as a protective envelope, encapsulating the substance until it has entered the cell inside the body,” says Christoph Hein, head of the Ultra- and High-precision Technology division at Fraunhofer IPK in Berlin.
To be able to produce the nanoparticles, the active ingredient dissolved in a buffer has to be mixed with another solution, such as a lipid solution. Once the two liquids have been combined, lipid nanoparticles are formed which in turn form a lipid envelope around the active ingredient.
“With the FDmiX platform, we can produce significantly smaller and more homogeneous particles and even adjust their size. FDmiX lets us produce mixtures of a previously unattainable level of homogeneity with very short mixing times. That’s relevant because the mixing quality not only determines the quality of the nanoparticles, but ultimately also how effective they are.”
Clever nozzle design leads to homogeneously mixed nanoparticles
But how can a high and consistent mixing quality be combined with throughput? The centerpiece of the FDmiX platform is an OsciJet nozzle from FDX Fluid Dynamix GmbH.
Inside the nozzle, a jet of liquid is positioned on one of the sides of the main chamber. Before leaving the nozzle, a small part of the jet is deflected into a side channel. At the end of the side channel, it meets the main jet again and pushes it to the other side. This causes the main jet to oscillate continuously from one side to the other at a high frequency.
In this way, the jet of lipid solution oscillating through the nozzle meets the stream of the mRNA active ingredient at a perpendicular angle, creating a homogeneous mixture with nanoparticles of uniform size.
In tests of conventional impinging mixers (also known as T-mixers or Y-mixers), by contrast, the lipid solution and mRNA active ingredient collide before flowing together through the same channel. This creates a dynamic vortex, resulting in inhomogeneous particles of lower quality.
“In encapsulation tests on mRNA in lipid nanoparticles using different mixers and flow rates, FDmiX generated smaller particles with significantly lower size distribution compared to a T-mixer at the same flow rate,” Hein explains.
In tests, the project partners produced nanoparticles about 10% to 20% smaller than those produced using a T-mixer. They also had significantly smaller size distribution and high encapsulation efficiency and particle integrity.
Large quantities of nanoparticles are needed during the clinical phase and the subsequent production stage. Here as well, the technology from Fraunhofer IPK and FDX Fluid Dynamix GmbH is impressive: The two project partners developed and tested mixers for various pressure and flow rates. The smallest mixers (FDmiX XS) can work at flow rates under 5 milliliters per minute, while the largest (FDmiX XL) can work at more than 1.5 liters per minute.
Broad range of applications for FDmiX nanoparticles
The nanoparticles produced in this way can be used for a wide range of applications, well beyond encapsulation of mRNA and stabilization of vaccines.
For example, this technology can also be used in cardiology for cardiac catheter coatings. When a balloon catheter is expanded during an examination, nanoparticles are absorbed into the arterial wall, preventing new deposits from forming there. This can help to prevent stenosis, or narrowing of the blood vessels.
Nanoparticles are also used in tumor therapy, and the molecules may also be helpful in treating neurodegenerative diseases such as Alzheimer’s and other forms of dementia.
Provided by Fraunhofer-Gesellschaft
News
The Silent Battle Within: How Your Organs Choose Between Mom and Dad’s Genes
Research reveals that selective expression of maternal or paternal X chromosomes varies by organ, driven by cellular competition. A new study published today (July 26) in Nature Genetics by the Lymphoid Development Group at the MRC [...]
Study identifies genes increasing risk of severe COVID-19
Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in [...]
Small regions of the brain can take micro-naps while the rest of the brain is awake and vice versa
Sleep and wake: They're totally distinct states of being that define the boundaries of our daily lives. For years, scientists have measured the difference between these instinctual brain processes by observing brain waves, with [...]
Redefining Consciousness: Small Regions of the Brain Can Take Micro-Naps While the Rest of the Brain Is Awake
The study broadly reveals how fast brain waves, previously overlooked, establish fundamental patterns of sleep and wakefulness. Scientists have developed a new method to analyze sleep and wake states by detecting ultra-fast neuronal activity [...]
AI Reveals Health Secrets Through Facial Temperature Mapping
Researchers have found that different facial temperatures correlate with chronic illnesses like diabetes and high blood pressure, and these can be detected using AI with thermal cameras. They highlight the potential of this technology [...]
Breakthrough in aging research: Blocking IL-11 extends lifespan and improves health in mice
In a recent study published in the journal Nature, a team of researchers used murine models and various pharmacological and genetic approaches to examine whether pro-inflammatory signaling involving interleukin (IL)-11, which activates signaling molecules such [...]
Promise for a universal influenza vaccine: Scientists validate theory using 1918 flu virus
New research led by Oregon Health & Science University reveals a promising approach to developing a universal influenza vaccine—a so-called "one and done" vaccine that confers lifetime immunity against an evolving virus. The study, [...]
New Projects Aim To Pioneer the Future of Neuroscience
One study will investigate the alterations in brain activity at the cellular level caused by psilocybin, the psychoactive substance found in “magic mushrooms.” How do neurons respond to the effects of magic mushrooms? What [...]
Decoding the Decline: Scientific Insights Into Long COVID’s Retreat
Research indicates a significant reduction in long COVID risk, largely due to vaccination and the virus’s evolution. The study analyzes data from over 441,000 veterans, showing lower rates of long COVID among vaccinated individuals compared [...]
Silicon Transformed: A Breakthrough in Laser Nanofabrication
A new method enables precise nanofabrication inside silicon using spatial light modulation and laser pulses, creating advanced nanostructures for potential use in electronics and photonics. Silicon, the cornerstone of modern electronics, photovoltaics, and photonics, [...]
Caught in the actinium: New research could help design better cancer treatments
The element actinium was first discovered at the turn of the 20th century, but even now, nearly 125 years later, researchers still don't have a good grasp on the metal's chemistry. That's because actinium [...]
Innovative Light-Controlled Drugs Could Revolutionize Neuropathic Pain Treatment
A team of researchers from the Institute for Bioengineering of Catalonia (IBEC) has developed light-activated derivatives of the anti-epileptic drug carbamazepine to treat neuropathic pain. Light can be harnessed to target drugs to specific [...]
Green Gold: Turning E-Waste Into a Treasure Trove of Rare Earth Metals
Scientists are developing a process inspired by nature that efficiently recovers europium from old fluorescent lamps. The approach could lead to the long-awaited recycling of rare earth metals. A small molecule that naturally serves [...]
Cambridge Study: AI Chatbots Have an “Empathy Gap,” and It Could Be Dangerous
A new study suggests a framework for “Child Safe AI” in response to recent incidents showing that many children perceive chatbots as quasi-human and reliable. A study has indicated that AI chatbots often exhibit [...]
Nanoparticle-based delivery system could offer treatment for diabetics with rare insulin allergy
Up to 3% of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the [...]
Nanorobot kills cancer cells in mice with hidden weapon
Researchers at Karolinska Institutet in Sweden have developed nanorobots that kill cancer cells in mice. The robot's weapon is hidden in a nanostructure and is exposed only in the tumor microenvironment, sparing healthy cells. [...]